Abstract | Thyroid-associated ophthalmopathy (TAO) is a vexing and undertreated ocular component of Graves disease in which orbital tissues undergo extensive remodelling. My colleagues and I have introduced the concept that fibrocytes expressing the haematopoietic cell antigen CD34 (CD34 + fibrocytes), which are precursor cells of bone-marrow-derived monocyte lineage, express the TSH receptor (TSHR). These cells also produce several other proteins whose expression was traditionally thought to be restricted to the thyroid gland. TSHR-expressing fibrocytes in which the receptor is activated by its ligand generate extremely high levels of several inflammatory cytokines. Acting in concert with TSHR, the insulin-like growth factor 1 receptor (IGF-1R) expressed by orbital fibroblasts and fibrocytes seems to be necessary for TSHR-dependent cytokine production, as anti-IGF-1R blocking antibodies attenuate these proinflammatory actions of TSH. Furthermore, circulating fibrocytes are highly abundant in patients with TAO and seem to infiltrate orbital connective tissues, where they might transition to CD34 + fibroblasts. My research group has postulated that the infiltration of fibrocytes into the orbit, their unique biosynthetic repertoire and their proinflammatory and profibrotic phenotype account for the characteristic properties exhibited by orbital connective tissues that underlie susceptibility to TAO. These insights, which have emerged in the past few years, might be of use in therapeutically targeting pathogenic orbit-infiltrating fibrocytes selectively by utilizing novel biologic agents that interfere with TSHR and IGF-1R signalling.
Introduction
Thyroid-associated ophthalmopathy (TAO) is an autoimmune process that affects the orbit and adjacent tissues of the upper face in patients with Graves disease. 1, 2 Unlike most other forms of autoimmunity, TAO is associated with a pattern of disease activity that is distinctive, frequently predictable and self-limited. 3 The disease is characterized by an initial active phase in which inflammation, tissue expansion and orbital congestion are dominant features. Over time, the disease progresses to a chronic, stable phase during which symptoms and ocular signs do not change. Mechanical restrictions resulting from pronounced fibrosis can often be observed during this phase. 4 Uncertainty persists as to why the orbit is specifically affected in Graves disease. Most investigators have focused on the orbital connective tissue as the primary site of autoimmune activity in TAO, 2, 5 whereas a minority believes that the extraocular muscles rather than the orbital connective tissue are the main target of immune system action. 6 The latter hypothesis is based largely on the detection of serum antibodies directed against several muscle proteins in individuals with TAO. 6 Intrinsic differences distinguish fat and connective tissues of the orbit from those of other regions of the body, such as the skin and lung. My research group has postulated that the unique properties of orbital fibroblasts could render the orbit susceptible to the characteristic inflammation, volume expansion and remodelling seen in patients with TAO. 4, 7 A pattern of gene expression that is characteristically associated with inflammation can be detected in affected orbital connective tissues, including the expression of several immediate early genes (genes that are involved in rapid defensive responses to danger signals from the environment). 8, 9 Many investigators believe that expression of the TSH receptor (TSHR), the central pathogenic autoantigen in Graves disease, by the orbital tissue underlies the develop ment of TAO. 2 In this Review, I attempt to introduce the concept that CD34 + fibrocytes are potential participants in the pathogenesis of TAO. These cells, which are derived from the monocyte lineage, express several proteins typically associated with the thyroid gland, including TSHR, and have been identified in the diseased orbit. 10 Given their striking immunological and biosynthetic properties, I believe that a strong case can be made for considering fibrocytes as prime candidates for therapeutic targeting in TAO.
interrogation of the protein structure and function of TSHR and the patterns of TSHR gene expression, as well as signalling following activation of the receptor, could be accomplished. Detailed characterization of the structure of the TSHR protein has enabled a better understanding of the involvement of this receptor in thyroid autoimmunity from a molecular point of view. 12 This research has yielded detailed mapping of immunogenic determinants of the TSHR protein and has revealed details of how TSHR signals within thyroid epithelial cells. [13] [14] [15] [16] [17] [18] [19] These insights have been invaluable in improving definition of the molecular basis of hyperthyroidism in Graves disease. In this process, activating antibodies known as thyroid-stimulating immunoglobulins (TSIs) trigger excessive production of thyroid hormones by mimicking the actions of TSH. 20 However, unlike the well-regulated production of TSH in the anterior pituitary gland, TSI production and activity are not subjected to negative feedback. Therefore, the trophic actions of TSIs can result in the hypermetabolism that is characteristic of Graves disease. 1 Of note, TSHR signalling in thyroid epithelial cells differs according to whether TSH or TSIs activate the receptor, with different signalling partners being involved in these processes. 19 Largely circumstantial evidence supports involvement of TSIs and TSHR in TAO. Detection of TSHR in tissues other than the thyroid gland suggests that the protein has functions other than regulating thyroid hormone production. These findings have generated interest in critically examining the physiological and pathological roles of TSHR from a broad point of view. Finding TSHR in orbital fat tissue and extraocular muscles 21 has prompted inquiry into whether the receptor might be involved in TAO. Theoretically, TSHR could participate in the pathogenesis of TAO in at least two distinct ways: first, as an autoantigen shared by the thyroid gland and the orbit; second, as a molecular conduit for diseaserelated signalling. Several studies have demonstrated detectable TSI levels in the vast majority of individuals with TAO, which suggests that TSIs could drive the pathogenesis of TAO. 22, 23 Some findings suggest that TSI levels are correlated with severity and activity of disease, [23] [24] [25] but adequately powered prospective studies that assess the relationship between TSI levels or activity and duration, severity or activity of TAO are awaited. Furthermore, the finding that TAO can manifest in individuals in whom TSIs are undetectable, in individuals with euthyroid Graves disease and in patients with Hashimoto thyroiditis complicates any comprehensive explanation for the involvement of TSHR in orbital disease pathogenesis.
On the other hand, the potential for a direct involvement of TSHR in TAO is implied by the promiscuous expression of the receptor in orbital connective tissues. Shortly after the molecular cloning of TSHR, its mRNA was detected in orbital connective tissue, regardless of whether the donor had TAO or not. 21 Orbital fibroblasts also express the receptor, although at extremely low levels in vitro compared with those found on thyroid epithelium. 26 This in vitro expression can be modestly enhanced by exposing orbital fibroblast cultures to conditions that favour adipocyte differentiation. 27 TSHR and TSHR expression have also been identified in several other tissues and cell types and thus seem not to be anatomically restricted to tissues ordinarily manifesting Graves disease. [28] [29] [30] [31] [32] Some reports have suggested that TSH and TSIs have direct effects on cultured orbital fibroblasts. [33] [34] [35] [36] Both molecules stimulate the synthesis of cytokines and hyaluronan, the principal glycosaminoglycan that accumulates in the orbit of patients with TAO. 4, 33, 36, 37 Whether signalling pathways downstream of TSHR in extrathyroidal tissues diverge when either TSH or TSIs activate the receptor, as seems to be the case in the thyroid gland, 19 has not yet been determined. Potentially important differences in signalling downstream of TSHR activation between thyroid epithelial cells and non-thyroid cells have been identified. TSH induces gene expression in fibrocytes that do not seem to express adenylate cyclase and in which TSHR signalling seems to be independent of cAMP generation. 33 Definition of how TSHR might contribute to TAO is currently the topic of substantial debate that centers not only on the putative function of the receptor within the orbit but also in other extrathyroidal regions and cell types, such as circulating cells originating in the bone marrow. An expanding appreciation of the potential physiological and pathological roles of TSHR in extrathyroidal tissues could help to define the potential of targeting this receptor as a therapeutic strategy in TAO. known as RANTES), a member of the IL-8 superfamily that activates T cells and monocytes. 42 Activation of orbital fibroblasts through the interaction between tumor necrosis factor receptor superfamily member 5 (also known as B-cell surface antigen CD40) and the CD40 ligand results in production of IL-6, IL-8 and C-C motif chemokine 2 (also known as monocyte chemoattractant protein 1, monocyte chemo tactic protein 1 or MCP-1; encoded by the gene CCL2). 43 Furthermore, interferon γ in combination with TNF induces MCP-1 and CXCL10 production in these cells. 44 These findings indicate that, under the influence of several stimuli, orbital fibroblasts can express and release multiple chemokines and other chemoattractants that are likely to underlie, at least in part, orbital tissue infiltration of a variety of immune mononuclear cells in TAO. The means by which balance among multiple homing signals is achieved in these infiltrating immune cells, however, remain uncertain. Another long-standing and as yet unanswered question is whether the pathogenic TSIs might directly initiate or in some manner promote mononuclear cell infiltration of the orbit.
Immune cell infiltration in TAO
The IGF-1 pathway in TAO Additional autoantigens besides TSHR could be relevant in Graves disease and TAO. Among these autoantigens, the insulin-like growth factor 1 receptor (IGF-1R) has received the most attention in the past few years. Evidence from studies of the IGF-1 pathway in both normal thyroid physiology and in TAO has contributed to this discussion.
IGF-1R as a putative autoantigen in TAO Three decades ago, antibodies of the immunoglobulin G (IgG) class from patients with TAO were shown to displace radiolabeled IGF-1 from the surfaces of cultured orbital fibroblasts. This finding implied that a specific IGF-1 binding site was recognized by these antibodies. 45 Although these studies failed to identify or characterize the nature of this fibroblast-specific binding site, they introduced the concept that the IGF-1 pathway might be involved in TAO. We now know that multiple proteins bind IGF-1 and IGF-2 with high affinity and high specificity, including IGF-1R and the family of IGFbinding proteins. 46 Subsequent studies revealed that IgGs from patients with Graves disease but not those from healthy individuals could induce production of IL-16 and RANTES in orbital fibroblasts of patients with TAO by activating the AKT/mTOR/p70S6K pathway. 47 The responses elicited by these IgGs were inhibited by rapamycin and glucocorticoids, which highlights the importance of mTOR in mediating these actions and suggests a role for NF-κB activation in these processes. In a more recent study from the same group, these activating IgGs were found to target IGF-1R. 48 Moreover, this receptor was found to be overexpressed by orbital fibroblasts of patients with TAO compared with those from healthy controls. No induction of either IL-16 or RANTES could be detected in fibroblasts from healthy donors. 48 Subsequent reports have either confirmed that anti-IGF-1R antibodies can be detected in at least a subset of patients with Graves disease, which contrasts with findings in healthy individuals, 49 or have failed to distinguish differences in the levels of anti-IGF-1R antibodies between healthy individuals and individuals with Graves disease. 50 The discrepancies between the findings from different studies might be related to a number of technical issues. Further refinement and standardization of experimental conditions and the design of assays that are best suited for detecting these antibodies will be neces sary before any firm conclusions can be drawn about whether IGF-1R is truly a second autoantigen in Graves disease and TAO. 51 Developing a means of distinguishing anti-IGF-1R antibodies that can activate the receptor from those that merely bind to it but fail to initiate signalling would be particularly important. Of note, in addition to IGF-1R being overexpressed in orbital fibroblasts from individuals with Graves disease, the frequency of T cells and B cells expressing IGF-1R seems to be increased when compared with that observed in healthy individuals.
52,53
Relationship between IGF-1 and TSH regulation Besides the potential role of IGF-1R and antibodies directed against this receptor in the pathogenesis of Graves disease, the IGF-1 pathway seems to share an intimate relationship with the physiological regulation of thyroid function by TSH. A study that reported the occurrence of either synergy or antagonism between TSH action and IGF-1 on thyroid epithelial cells in culture provided initial evidence for this involvement. 54 The study demonstrated that IGF-1 could enhance the stimulatory effects of TSH on proliferation of FRTL-5 rat thyroid cells. By contrast, IGF-1 dampens the induction of the sodium/iodide cotransporter (SLC5A5, also known as NIS) by TSH, an action that is mediated by PI3 kinase. 50 IGF-1 and TSH synergistically enhance 1,2-diacylglycerol production in rat thyroid cells. 51 In 2014, TSH and IGF-1 were reported to drive an increase in nuclear accumulation of β-catenin and in so doing enhance thyroid epithelial cell proliferation in a Wnt-independent manner. 52 Other studies have shown that IGF-1R seems to have an indispensable role in specific aspects of TSHR signalling. In mice in which tissue-specific IGF-1R expression was knocked out in the thyroid gland, levels of circulating TSH were increased and T 4 levels were decreased. 53 Conversely, overexpressing IGF-1R in the thyroid gland reduced the TSH concentration requirement for n ormalizing the synthesis of thyroid hormones. 54 One study showed that IGF-1R and TSHR form a physical complex in orbital fibroblasts and thyroid epithelial cells. 60 Interrupting IGF-1R-dependent signalling with an IGF-1R-blocking antibody could attenuate the downstream signalling events triggered by TSH and TSI engagement with TSHR. Furthermore, the report contained evidence for colocalization of TSHR and IGF-1R, as assessed by confocal microscopy and through coprecipita tion pull-down studies. Dependence on IGF-1R for TSHR-initiated signalling in orbital fibroblasts has been confirmed by another research group. 37 The potential involvement of IGF-1R and activating antibodies against this receptor in TAO, including the possible role of IGF-1R in mediating actions initiated by TSH and/or TSIs on extrathyroidal tissues, has provoked lively discussions. While strong opinions have been voiced regarding whether IGF-1R or TSHR is a more important autoantigen in TAO, 61 essentially nothing is currently known about the relative contributions of either receptor to pathophysiological events occurring in the orbit in vivo. Thus, determination of the merits of either side of the debate will necessarily await further study.
Thyroid antigens in the orbit
In one of the first studies that suggested that proteins thought to be restricted to the thyroid gland could also be present in the orbit, thyroidolymphography was used to examine lymphatic drainage in patients with Graves disease who had hyperthyroidism. 62 After injection of 99 mTc sulfur colloid directly into the hyperplastic thyroid glands of these patients, the tracer rapidly moved into their lymphatic system. On the basis of these observations, the study researchers proposed that thyroid antigens such as thyroglobulin might translocate from the thyroid gland to the orbit in patients with TAO. The same research group successfully immunized mice with human extraocular muscle extracts, which resulted in the generation of antibodies against thyroglobulin (which is encoded by the gene TG). 63 Subsequently, intact thyroglobulin was detected in orbital tissues from individuals with TAO (but not in those from healthy donors) and T 4 was also detected in the same material. 64 These findings led to the conclusion that the thyroglobulin found in orbital tissues had probably originated in the thyroid and translocated to the orbit. 64 This research group also found that thyroglobulin in orbital tissues formed a complex with glycosaminoglycans. 65 Furthermore, a potential relationship between orbital thyroglobulin content and previous treatment with radioactive iodine was identified; however, the mechanism underlying this relationship is uncertain. 66 
Role of orbital fibroblasts in TAO
Response to inflammatory mediators The repertoire of proteins expressed by orbital fibroblasts 67 and their particularly robust responses to inflammatory cytokines seem to set these cells apart from fibroblasts located in other anatomic regions. Evidence suggests that orbital fibroblasts from patients with TAO and those from healthy individuals are inherently different with regard to the magnitude of response to cytokines and growth factors. 68 In addition, external molecular cues derived from infiltrating mononuclear cells might have important roles in regulating orbital fibroblast behaviour in situ. 69, 70 Members of the IL-1 cytokine family are examples of these cues. In particular, IL-1β frequently elicits a dramatic induction of genes such as those encoding other inflammation-related proteins, including IL-6 and IL-8, 71, 72 other chemokines and chemoatractants (IL-16, RANTES), 42 and enzymes involved in the synthesis of immune mediators of inflammation. 73, 74 Notable enzymes that are differentially induced in orbital fibroblasts of patients with TAO compared with those from healthy donors or cells derived from the skin include arachidonate 15-lipoxygenase 73 and prostaglandin G/H synthase 2 74 (also known as PGHS-2 or COX-2, the inflammatory cyclooxygenase), which in turn leads to differential production of 15-HETE (15-hydroxyeicosatetraenoic acid) and prostaglandin E 2 , respectively. A peculiar profile of IL-1 receptor antagonist (IL-1RA) isoforms seems to be among the factors underlying these exaggerated responses to cytokines. 75 The patterns of expression of these IL-1RA isoforms in orbital fibroblasts diverge from those identified in fibroblasts from other connective tissue depots. 75 The relatively low level of secreted IL-1RA (sIL-1RA) generated by orbital fibroblasts compared with the level generated from skin cells in response to multiple stimuli is of particular note. This molecule acts as a dominant modu lator of IL-1 actions; 76 therefore, low levels of sIL-1RA render orbital fibroblasts particularly susceptible to the actions of IL-1β. By contrast, intracellular IL-1RA (icIL-1RA) is highly expressed by orbital fibroblasts. Whereas this isoform attenuates responses downstream of the IL-1 receptor, it does not block the actions of exogenous IL-1β. 77 IL-1RA expression is stimulated by several factors in these cells, including IL-1β and TSH. 75, 78 A report published in 2014 revealed the modulatory influence of phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (also known as phosphatase and tensin homologue) on IL-1RA induction by TSH in fibroblasts, as well as that of IL-1α and IL-1β. 79 The array of inflammatory genes, as well as their modulators, expressed in orbital connective tissues might determine the magnitude and duration of immune reactivity in TAO.
Hyaluronan production and adipogenesis
The propensity of soft tissues to expand in TAO is a consequence, at least in part, of an accumulation of hyaluronan. This accumulation seems to be associated with increased de novo adipogenesis, which results in increased fat tissue volume. Orbital fibroblasts express the molecular machinery necessary for hyaluronan synthesis, including the enzymes UDP-glucose 6-dehydrogenase protein 80, 81 and the terminal hyaluronan synthases, of which three have been identified in mammals. 82, 83 When activated by cytokines such as IL-1β, CD40 ligand, leukoregulin, as well as prostaglandin D 2 and growth factors such as IGF-1 and TSH, orbital fibroblasts express increased levels of the enzymes involved in hyaluronan synthesis, which results in accelerated hyaluro nan production. 36, [84] [85] [86] [87] Whether the accumulation of hyaluronan in the orbit of patients with TAO results entirely from altered rates of synthesis or also from delayed macro molecular degradation remains uncertain. The chain length of the hyaluronan molecule is an important determinant of its biological effect. 88 Therefore, a systematic analysis of hyaluronan and investigating whether the characteristics of this molecule change in TAO are necessary for a better understanding of the roles of hyaluronan in TAO. Furthermore, the relative abundance of other glyco saminoglycans, such as chondroitin sulfate, heparan sulfate and dermatan sulfate, in the orbit of patients with TAO has yet to be quantified.
Cellular heterogeneity
Recognition that the behaviour of orbital fibroblasts in vitro is substantially different from that of fibroblasts derived from other tissues has prompted a thorough examination of their distinguishing phenotypic attributes, including their embryonic lineages. Determination of the origins of the components of orbital connective tissue and of its fate and interaction with epithelial elements can be traced to the work of Drew Noden. 89 Among its peculiar attributes, orbital fat tissue comprises a heterogeneous population of fibroblast-like cells. Fibroblasts derived from this fat tissue can be divided into discrete populations on the basis of the cell surface molecules they display. 90 Despite sharing similar morphologies 91 and ultrastructure 92 in culture, these subpopulations of cells exhibit distinct properties. 90, [93] [94] [95] [96] [97] Fibroblasts from healthy orbital connective tissues as well as those from individuals with TAO can be divided into two subsets on the basis of expression of Thy-1 (also known as CD90), a membranespanning glycoprotein. Thy-1 + and Thy-1 -cells exhibit divergent patterns of terminal differentiation. 95 Thy-1 + cells express smooth-muscle-specific α-actin and develop into myofibroblasts when treated with TGF-β. By contrast, Thy-1 -fibroblasts express high levels of peroxisome proliferator-activated receptor γ (PPARγ) and exposure of these cells to thiazolidinediones results in accumulation of lipid droplets in the cytoplasm and expression of genes encoding lipogenic enzymes. Differences in these cell subsets were identified in 2014 using a three-dimensiona l model. 97 Responses to cytokines such as IL-1β seem to differ in the two subsets. 96 Other studies have demonstrated a molecular interplay between Thy-1 + and Thy-1 -orbital fibroblasts. 98 Thy-1 + orbital fibroblasts were found to secrete a soluble factor that seems to prevent cells of that phenotype from differentiating into adipocytes. The actions of this inhibitory factor can be mediated by altering the binding of PPARγ to the target genes it regulates. 98 Therefore, the balance between Thy-1 + and Thy-1 -fibroblasts might determine whether orbital tissues undergo adipogenic differentiation or fibrosis. Further investigation into the relationship between these orbital fibroblast subsets, including improved definition of their phenotypic attributes and biosynthetic repertoires, could yield fundamental insights into the biology of tissue changes a ssociated with TAO.
Infiltrating CD34 + fibrocytes and TAO
Fibrocytes are monocyte-lineage progenitors from the bone marrow that have been implicated in many aspects of wound healing, tissue remodelling, and immune function. 99, 100 These cells have been associated with several conditions that trigger repair processes, including thermal burns, 101 glomerular disease, 102 hepatic fibrosis, 103 asthma, 104 and rheumatoid arthritis. 105 Fibrocytes are characterized by a specific pattern of protein expression and display of cell surface markers. 106 This pattern includes the expression of receptor-type tyrosine-protein phosphatase C (also known as CD45), C-X-C chemokine receptor type 4 (CXCR-4) and CD34, and the production of collagen I. Fibrocytes can terminally differentiate into either myofibroblasts or adipocytes depending on the molecular environment in which they are located. 107 Specifically, when exposed to PPARγ activators, they accumulate triglycerides and differentiate into mature adipocytes. By contrast, when activated in vitro through the Smad pathway by treatment with TGF-β, they differentiate into myofibroblasts and express high levels of smooth-muscle-specific α-actin. Fibrocytes have roles in immune function, including the ability to present antigens through major histo compatibility complex class II molecules to T cells.
108 Fibrocytes are extremely rare in the circulation of healthy individuals, in whom they account for less than 1% of mononuclear cells. The abundance of fibrocytes increases dramatically in certain pathological states, such as those associated with extensive tissue injury. 109, 110 In thermal burns, for example, these cells not only circulate in great abundance but also infiltrate affected tissues. 111 This homing occurs through chemokine activities. Animal-based studies have implicated a network involving CXCR-4 and stromal cellderived factor 1 (encoded by the gene CXCL12) as an important determinant of the localization of fibrocytes that are involved in the pathogenesis of lung fibrosis. 112 The frequency of circulating CD34 + fibrocytes was reported to be substantially increased in Graves disease (Figure 1a) . 10 These cells were detected in situ in orbital fat tissue of patients with TAO but seem to be absent in tissues from healthy individuals (Figures 1b,c) . The researchers identified an abundant subset of orbital fibroblasts from patients with TAO that expressed CD34 + and CXCR-4 + but not platelet endothelial cell adhesion molecule (CD31), which suggests that these cells evolved from CD34 + fibrocytes that had infiltrated orbital tissues. These fibroblasts no longer expressed CD45 but produced collagen I. In the orbit of patients with TAO, CD34
+ fibroblasts reside in a cellular context that includes CD34 -fibroblasts, which are thought to be identical to fibroblasts that are uniformly present in healthy tissues. As both fat tissue expansion and fibrosis represent important components of tissue remodelling associated with TAO, fibrocytes have been proposed as prime candidates for therapeutic targeting. 113 Fibrocytes are characterized by a high level of TSHR mRNA expression that is unprecedented in the extrathyroidal compartment. 10 The steady-state abundance of this transcript is considerably lower than that found in thyroid tissue, but the levels of surface expression of the protein seem to be equivalent on fibrocytes and thyroid epithelial cells and are substantially higher than those found on orbital fibroblasts (Figure 2) . 60 The presence of TSHR on fibrocytes suggests that the receptor might mediate actions of TSH and TSIs locally in the connective tissue compartment. 7 Several reports have documented the responses of fibrocytes to TSH and M22, a monoclonal antibody that activates TSHR. These studies have demonstrated increases in the production of cytokines, including IL-1β, IL-1RA, TNF, IL-6, IL-8 and MCP-1 following treatment of fibrocytes with either TSH or M22 (Figure 3) . 8, 33, 78, 114 These responses seem to be qualitatively similar in fibrocytes from patients with TAO and healthy individuals but the magnitude of response seems to be greater in the former group. 114 In contrast to fibrocytes, orbital fibroblasts from patients with TAO exhibit substantially less robust responses to TSH. 33 The divergence in the magnitude of the responses might be attributed to higher TSHR levels in fibrocytes than in fibroblasts and to qualitative differences in the relevant post-receptor signalling pathways.
Besides TSHR, other proteins previously thought to be thyroid-specific, such as thyroglobulin, 115 NIS and thyroid peroxidase (TPO) are also expressed by cultured fibrocytes. 116 The levels of these proteins are substantially lower than those found in the thyroid gland, but they are still readily detectable using standard techniques. Fibrocyteexpressed thyroglobulin can incorporate iodine, a process that seems to be TSH-independent. As with TSHR, the mRNAs of TG, NIS and TPO are considerably less abundant in orbital fibroblasts from patients with TAO than in cultured fibrocytes from both patients with TAO and healthy individuals, and the respective proteins are expressed at low but detectable levels in fibroblasts. 115, 116 The expression of TSHR and thyroglobulin by infiltrating fibrocytes could, therefore, account for the low but still detectable levels of both proteins in the orbital tissues of patients with TAO. 21, [62] [63] [64] [65] [66] In addition to proteins associated with thyroid function and disease, fibrocytes express auto antigens that are associated with type 1 diabetes mellitus. 118 The identification of autoimmune regulator (also known as APECED protein, encoded by the gene AIRE), a nontraditional transcription factor (which acts on multiple genes), as an essential participant in the expression of TSHR, thyro globulin, NIS and TPO by fibrocytes 116 is of potential importance for understanding these molecu lar pathways and could have therapeutic implications. Knocking down AIRE expression substantially reduces the levels of all of these 'thyroid-specific' proteins. Of note, the expression of TSHR, TG, NIS and TPO mRNAs in a patient with a loss-of-function AIRE mutation was similarly reduced (Figure 4a) .
Studies in the past 2 years have disclosed interactions between native (CD34 -) orbital fibroblasts and CD34 + orbital fibroblasts, which are thought to derive from CD34 + fibrocytes. Signals from CD34 -fibroblasts seem to repress the expression of 'thyroid-specific' proteins, thereby accounting for their decreased levels as fibrocytes transition to CD34 + orbital fibroblasts. 115, 116 When CD34 + fibroblasts are purified by cytometric cell sorting from parental orbital fibroblast strains, which comprise a mixture of CD34 + and CD34 -cells, they display dramatically higher expression of 'thyroid-specific' mRNAs than does the mix of CD34 + and CD34 -cells (Figure 4b) . 115, 116 These findings have substantial implications for understanding the potential mechanisms through which aspects of the CD34 + fibroblast pheno type might be modulated by CD34 -fibroblasts. The reper toire of antigens expressed by fibrocytes infiltrating the orbit in TAO might be governed by the capacity of native CD34 -fibroblasts to modulate their diversity and levels of gene expression. In so doing, these CD34 -fibroblasts might influence the pathogenic immune responses in TAO. Figure 5 illustrates the roles CD34 + fibrocytes and fibroblasts and CD34
-fibroblasts seem to have in the pathogenesis of TAO on the basis of research findings from the past few years.
Potential therapeutic implications
In my view, the fairly high-level expression of functional TSHR identified in fibrocytes and the apparent Figure 4 | mRNAs encoding proteins previously thought to be thyroid-specific are detectable in fibrocytes and CD34 + orbital fibroblasts. a | Fibrocytes derived from an individual with APS-1 express lower mRNA levels of AIRE, TSHR, TG, NIS, TPO, PAX8, and TTF1 than do fibrocytes from an unaffected first-degree relative. Fibrocytes from the peripheral blood mononuclear cell lineage were obtained from an individual with APS-1 and her unaffected mother. The proband was heterozygous for two mutations, a C>T substitution at bp 769 and a 13-base deletion from bp 967 to bp 979. Cultures were harvested after 14 days, after which real-time PCR was performed. Data are expressed as mean ± SD (n = 6 independent determinations). b | After sorting orbital fibroblasts from a patient with Graves disease into CD34 + and CD34 -subsets, dramatic elevations in AIRE mRNA levels, as well as in TG, TSHR, NIS and TPO mRNA levels (owing to the increased expression of AIRE) were seen in CD34 + cells. A parental strain of orbital fibroblasts from a patient with Graves disease containing a mixture of CD34 + and CD34 -fibroblasts was sorted into pure CD34 + and CD34 -subsets by fluorescence-activated cell sorting. These cells were cultured for 48 h, after which RNA was extracted and reverse-transcribed; real-time PCR for the amplicons indicated was then performed. Abbreviation: APS-1, autoimmune polyendocrine syndrome type 1. Adapted with minor modifications with permission of Endocrine Society from Fernando infiltration of these cells into the orbit of patients with TAO might be exploited therapeutically. Strategies for interrupting TSHR signalling are being developed and the properties of these agents seem to make them promis ing as potential drugs. Highly selective small-molecule antagonists of TSHR have been developed, including an agent designated ANTAG3 that dem onstrates activity in vitro as well as in mice. 119 Stimulatory and blocking antibodies targeting TSHR have also been developed 120, 121 and their divergent interactions with the target receptor have been scrutinized in great detail. 122 Either approach might prove effective in reducing the effect of the inflammatory pheno type exhibited by TSH-stimulated fibrocytes on the pathogenesis of TAO. Alternatively, targeting IGF-1R signalling with a blocking antibody such as tepro tumamab (a human monoclonal anti-IGF-1R antibody) has been shown to substantially decrease TSHR-mediated IL-6 expressed in fibrocytes. 123 These findings strongly suggest that interruption of the IGF-1R pathway in these cells might be another therapeutic approach in TAO. A multicenter placebo-controlled study, the largest therapeutic trial for TAO ever conducted in North America, is currently examining the safety and efficacy of teprotumamab in patients with severe, active TAO. 124 Strategies as yet untested but worthy of investigation include approaches that interfere with fibrocyte infiltration, such as those interrupting relevant chemokine pathways. Emerging insights into the biology of the orbit are likely to yield more effective treatments for TAO.
Conclusions
Research in the past few years has shown that circulating bone-marrow-derived fibrocytes are more numerous in patients with Graves disease and TAO than in healthy individuals. In patients with TAO, these fibrocytes apparently infiltrate the orbit, where they seem to transition into a subset of orbital fibroblasts. Fibrocytes express fairly high levels of functional TSHR, to which TSH and TSIs bind and which they activate, which leads to the expression of an array of inflammatory genes including those encoding cytokines. TSHR signalling in fibrocytes and orbital fibroblasts seems to be dependent, at least in part, on functional IGF-1R. Taken together, these findings implicate fibrocytes in the pathogenesis of TAO. When evaluating this evidence, the reader must consider that all of these findings come from a single research laboratory. This work must therefore be independently corroborated by others and expanded to in vivo models before any firm conclusions can be drawn. + fibroblasts are associated with increased inflammation and adipocyte and myofibroblast differentiation. The expression of proteins previously thought to be thyroid-specific, such as thyroglobulin, TPO, sodium/iodide cotransporter SLC5A5 (also known as NIS) and TSHR, by fibrocytes and CD34 + orbital fibroblasts is mediated by autoimmune regulator (also known as APECED protein, encoded by the AIRE gene) and might be downregulated by a factor or factors (yet unknown) generated by CD34 -fibroblasts. The effectiveness of CD34 -fibroblasts in modulating the CD34 + phenotype might then determine whether the individual with Graves disease develops TAO and, if so, the severity, duration, and activity of this orbital disease. Abbreviation: TAO, thyroid-associated ophthalmopathy.
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